Drug intelligence / Profile preview

60.11

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

60.11 is a monoclonal antibody designed to target gC1qR (also known as p32/HABP1), a complement receptor overexpressed in mesothelioma. It specifically binds to the C1q binding domain of gC1qR, located at amino acids 76–93, thereby blocking its function. This action has been shown to reduce mesothelioma tumor growth by inhibiting cell proliferation, increasing cellular apoptosis, and impairing angiogenesis. The drug is being investigated as a potential novel therapeutic strategy for mesothelioma.

Beyond the preview

Go deeper on 60.11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60.11.

Explore the full profile